Roscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear localization, transcription, and episome maintenance

Journal of Virology

Volumn 85, Issue 6, 2011, Pages 2859-2868

  Kang, Myung Soo ^a,b   Lee, Eun Kyung ^b   Soni, Vishal ^a,c   Lewis, Timothy A ^d   Koehler, Angela N ^d   Srinivasan, Viswanathan ^a,e   Kieff, Elliott ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Sungkyunkwan University   (South Korea)

^c Virid Biosciences LLC   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e Beckman Coulter Genomics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B; EPSTEIN BARR VIRUS ANTIGEN 1; ROSCOVITINE; SERINE;

ARTICLE; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; EPISOME; ESCHERICHIA COLI; GROWTH INHIBITION; HUMAN; IMMUNOPRECIPITATION; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION;

ANTIVIRAL AGENTS; DRUG EVALUATION, PRECLINICAL; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; ESCHERICHIA COLI; HERPESVIRUS 4, HUMAN; HUMANS; PHOSPHORYLATION; PLASMIDS; PURINES; TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

ESCHERICHIA COLI; HUMAN HERPESVIRUS 4;

EID: 79952426758     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01628-10     Document Type: Article

References (87)

1. Adams, A., and T. Lindahl. 1975. Epstein-Barr virus genomes with properties of circular DNA molecules in carrier cells. Proc. Natl. Acad. Sci. U. S. A. 72:1477-1481.
2. Aiyar, A., and B. Sugden. 1998. Fusions between Epstein-Barr viral nuclear antigen-1 of Epstein-Barr virus and the large T-antigen of simian virus 40 replicate their cognate origins. J. Biol. Chem. 273:33073-33081.
3. Ballestas, M. E., P. A. Chatis, and K. M. Kaye. 1999. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 284:641-644.
4. Bashir, R., J. Luka, K. Cheloha, M. Chamberlain, and F. Hochberg. 1993. Expression of Epstein-Barr virus proteins in primary CNS lymphoma in AIDS patients. Neurology 43:2358-2362. (Pubitemid 23346977)
5. Benson, C. R., et al. Pharmacokinetics (PK) of the oral cyclin dependent kinase inhibitor CYC202 (R-roscovitine) in patients with cancer. 92nd Annual Meeting of the American Association for Cancer Research, San Francisco, CA.
6. Bochkarev, A., et al. 1996. Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA. Cell 84:791-800. (Pubitemid 26094208)
7. Bochkarev, A., E. Bochkareva, L. Frappier, and A. M. Edwards. 1998. The 2.2 A structure of a permanganate-sensitive DNA site bound by the Epstein- Barr virus origin binding protein, EBNA1. J. Mol. Biol. 284:1273-1278. (Pubitemid 28566065)
8. Bossolasco, S., et al. 2001. Soluble CD23 in cerebrospinal fluid: a marker of AIDS-related non-Hodgkin's lymphoma in the brain. AIDS 15:1109-1113. (Pubitemid 32549861)
9. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
10. Bresnahan, W. A., I. Boldogh, P. Chi, E. A. Thompson, and T. Albrecht. 1997. Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication. Virology 231:239-247. (Pubitemid 27244190)
11. Bukanov, N. O., L. A. Smith, K. W. Klinger, S. R. Ledbetter, and O. Ibraghimov- Beskrovnaya. 2006. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 444:949-952. (Pubitemid 46025010)
12. Cho, Y. C., and C. R. Jefcoate. 2004. PPARgamma1 synthesis and adipogenesis in C3H10T1/2 cells depends on S-phase progression, but does not require mitotic clonal expansion. J. Cell Biochem. 91:336-353.
13. Coley, H. M., C. F. Shotton, and H. Thomas. 2007. Seliciclib (CYC202; R-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines. Anticancer Res. 27:273-278. (Pubitemid 46363342)
14. Dambaugh, T., et al. 1980. Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping. Proc. Natl. Acad. Sci. U. S. A. 77:2999-3003.
15. De Azevedo, W. F., et al. 1997. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243:518-526.
16. Dey, A., E. T. Wong, C. F. Cheok, V. Tergaonkar, and D. P. Lane. 2008. R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ. 15(2):263-273.
17. Diella, F., C. M. Gould, C. Chica, A. Via, and T. J. Gibson. 2008. Phospho. ELM: a database of phosphorylation sites - update 2008. Nucleic Acids Res. 36:D240-D244.
18. Diwan, P., J. J. Lacasse, and L. M. Schang. 2004. Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors. J. Virol. 78:9352-9365.
19. Duellman, S. J., K. L. Thompson, J. J. Coon, and R. R. Burgess. 2009. Phosphorylation sites of Epstein-Barr virus EBNA1 regulate its function. J. Gen. Virol. 90:2251-2259.
20. Fabian, M. A., et al. 2005. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23:329-336.
21. Faulkner, G. C., et al. 1999. X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus. J. Virol. 73:1555-1564. (Pubitemid 29036811)
22. Fax, P., O. Lehmkuhler, C. Kuhn, H. Esche, and D. Brockmann. 2000. E1A12S-mediated activation of the adenovirus type 12 E2 promoter depends on the histone acetyltransferase activity of p300/CBP. J. Biol. Chem. 275: 40554-40560.
23. Fischer, P. M., and A. Gianella-Borradori. 2003. CDK inhibitors in clinical development for the treatment of cancer. Expert Opin. Invest. Drugs 12(6): 955-970.
24. Frappier, L., and M. O'Donnell. 1991. Overproduction, purification, and characterization of EBNA1, the origin binding protein of Epstein-Barr virus. J. Biol. Chem. 266:7819-7826.
25. Geser, A., G. de The, G. Lenoir, N. E. Day, and E. H. Williams. 1982. Final case reporting from the Ugandan prospective study of the relationship between EBV and Burkitt's lymphoma. Int. J. Cancer 29:397-400.
26. Ghedin, E., et al. 2003. Pharmacological cyclin dependent kinase inhibitors inhibit immediate early gene expression of HHV8, abstr. 34. 7th International Conference on Malignancies in AIDS and Other Immunodeficiencies, Bethesda, MD.
27. Goodyear, S., and M. C. Sharma. 2007. Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5. Exp. Mol. Pathol. 82:25-32.
28. Gray, N. S., et al. 1998. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281:533-538. (Pubitemid 28357362)
29. Guderian, G., et al. 16 November 2010, posting date. RioK1, a new interactor of protein arginine methyltransferase 5 (PRMT5), competes with pICln for binding and modulates PRMT5 complex composition and substrate specificity. J. Biol. Chem. doi:10.1074/jbc.M110.148486.
30. Hahntow, I. N., et al. 2004. Cyclin-dependent kinase inhibitor roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 18:747-755. (Pubitemid 38500193)
31. Hammarskjöld, M. L., S. C. Wang, and G. Klein. 1986. High-level expression of the Epstein-Barr virus EBNA1 protein in CV1 cells and human lymphoid cells using a SV40 late replacement vector. Gene 43:41-50. (Pubitemid 16011523)
32. Hearing, J. C., and A. J. Levine. 1985. The Epstein-Barr virus nuclear antigen (BamHI K antigen) is a single-stranded DNA binding phosphoprotein. Virology 145:105-116.
33. Henderson, A., S. Ripley, M. Heller, and E. Kieff. 1983. Chromosome site for Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes growth-transformed in vitro. Proc. Natl. Acad. Sci. U. S. A. 80:1987-1991.
34. Henle, W., G. Henle, and J. H. Ho. 1978. Epstein-Barr virus-related serology in nasopharyngeal carcinoma and controls. IARC Sci. Publ. 20:427-437.
35. Hirt, B. 1967. Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 26:365-369.
36. Hong, M., et al. 2006. Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells. J. Cancer Res. Clin. Oncol. 132:1-8.
37. Hung, M. L., G. M. Hautbergue, A. P. Snijders, M. J. Dickman, and S. A. Wilson. 2010. Arginine methylation of REF/ALY promotes efficient handover of mRNA to TAP/NXF1. Nucleic Acids Res. 38:3351-3361.
38. Hung, S. C., M. S. Kang, and E. Kieff. 2001. Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBV-encoded nuclear antigen-1 chromosome-binding domains, which can be replaced by high-mobility group-I or histone H1. Proc. Natl. Acad. Sci. U. S. A. 98:1865-1870.
39. Ibraghimov-Beskrovnaya, O. 2007. Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy. Cell Cycle 6:776-779. (Pubitemid 46572612)
40. Imai, S., M. Kuroda, R. Yamashita, and Y. Ishiura. 2005. Therapeutic inhibition of Epstein-Barr virus-associated tumor cell growth by dominant-negative EBNA1. Uirusu 55:239-249.
41. Ito, S., et al. 2000. Epstein-Barr virus nuclear antigen-1 binds to nuclear transporter karyopherin alpha1/NPI-1 in addition to karyopherin alpha2/ Rch1. Virology 266:110-119. (Pubitemid 30048641)
42. Kitamura, R., et al. 2006. Nuclear import of Epstein-Barr virus nuclear antigen 1 mediated by NPI-1 (importin alpha5) is up- and down-regulated by phosphorylation of the nuclear localization signal for which Lys379 and Arg380 are essential. J. Virol. 80:1979-1991. (Pubitemid 43228738)
43. Kudoh, A., et al. 2004. Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication. J. Virol. 78:104-115. (Pubitemid 37549723)
44. Kuehn, E. W., and G. Walz. 2007. Prime time for polycystic kidney disease: does one shot of roscovitine bring the cure? Nephrol. Dial. Transplant. 22:2133-2135.
45. Lemercier, C., et al. 2003. Tip60 acetyltransferase activity is controlled by phosphorylation. J. Biol. Chem. 278:4713-4718.
46. Li, N., et al. 2010. Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS One 5:e10126.
47. Lindahl, T., G. Klein, B. M. Reedman, B. Johansson, and S. Singh. 1974. Relationship between Epstein-Barr virus (EBV) DNA and the EBV-determined nuclear antigen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignancies. Int. J. Cancer 13:764-772.
48. Mackey, D., and B. Sugden. 1999. The linking regions of EBNA1 are essential for its support of replication and transcription. Mol. Cell. Biol. 19:3349-3359.
49. MacMahon, E. M., et al. 1991. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 338:969-973.
50. Mapelli, M., et al. 2005. Mechanism of CDK5/p25 binding by CDK inhibitors. J. Med. Chem. 48:671-679.
51. Martin, G., et al. 2010. Arginine methylation in subunits of mammalian pre-mRNA cleavage factor I. RNA 16:1646-1659.
52. Matsuo, T., M. Heller, L. Petti, E. O'Shiro, and E. Kieff. 1984. Persistence of the entire Epstein-Barr virus genome integrated into human lymphocyte DNA. Science 226:1322-1325. (Pubitemid 15215585)
53. Meijer, L., et al. 1997. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243:527-536.
54. Mgbonyebi, O. P., J. Russo, and I. H. Russo. 1999. Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res. 59:1903-1910.
55. Nasimuzzaman, M., et al. 2005. Eradication of Epstein-Barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1. Mol. Ther. 11:578-590.
56. Nonoyama, M., and J. S. Pagano. 1972. Separation of Epstein-Barr virus DNA from large chromosomal DNA in non-virus-producing cells. Nat. New Biol. 238:169-171.
57. Nutley, B. P., et al. 2005. Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. Mol. Cancer Ther. 4:125-139.
58. Park, J. Y., et al. 2007. p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels. BMC Nephrol. 8:12.
59. Rawlins, D. R., G. Milman, S. D. Hayward, and G. S. Hayward. 1985. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell 42:859-868.
60. Raynaud, F. I., et al. 2005. In vitro and in vivo pharmacokinetic- pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin. Cancer Res. 11:4875-4887.
61. Reisman, D., and B. Sugden. 1986. trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol. Cell. Biol. 6:3838-3846.
62. Rickinson, A. B., and E. D. Kieff. 2007. Epstein-Barr virus, p. 2655-2700. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 5th ed., vol. 2. Lippincott Williams & Wilkins, Philadelphia, PA.
63. Roth, G., T. Curiel, and J. Lacy. 1994. Epstein-Barr viral nuclear antigen 1 antisense oligodeoxynucleotide inhibits proliferation of Epstein-Barr virus-immortalized B cells. Blood 84:582-587. (Pubitemid 24215960)
64. Sanchez, S. E., et al. 2010. A methyl transferase links the circadian clock to the regulation of alternative splicing. Nature 468:112-116.
65. Schang, L. M. 2005. Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs. Curr. Drug Targets Infect. Disord. 5:29-37.
66. Schang, L. M. 2002. Cyclin-dependent kinases as cellular targets for antiviral drugs. J. Antimicrob. Chemother. 50:779-792.
67. Schang, L. M. 2004. Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication. Biochim. Biophys. Acta 1697:197-209.
68. Sears, J., et al. 2004. The amino terminus of Epstein-Barr virus (EBV) nuclear antigen 1 contains AT hooks that facilitate the replication and partitioning of latent EBV genomes by tethering them to cellular chromosomes. J. Virol. 78:11487-11505. (Pubitemid 39390736)
69. Sivachandran, N., J. Y. Cao, and L. Frappier. 2010. Epstein-Barr virus nuclear antigen 1 hijacks the host kinase CK2 to disrupt PML nuclear bodies. J. Virol. 84:11113-11123.
70. Sixbey, J. W., et al. 1983. Replication of Epstein-Barr virus in human epithelial cells infected in vitro. Nature 306:480-483. (Pubitemid 14235570)
71. Sun, X., et al. 2010. Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism. Proc. Natl. Acad. Sci. U. S. A. 107:3146-3151.
72. Thompson, S., T. Messick, D. C. Schultz, M. Reichman, and P. M. Lieberman. 2010. Development of a high-throughput screen for inhibitors of Epstein- Barr virus EBNA1. J. Biomol. Screen. 15:1107-1115.
73. van Engeland, M., H. J. Kuijpers, F. C. Ramaekers, C. P. Reutelingsperger, and B. Schutte. 1997. Plasma membrane alterations and cytoskeletal changes in apoptosis. Exp. Cell Res. 235:421-430.
74. Van Scoy, S., I. Watakabe, A. R. Krainer, and J. Hearing. 2000. Human p32: a coactivator for Epstein-Barr virus nuclear antigen-1-mediated transcriptional activation and possible role in viral latent cycle DNA replication. Virology 275:145-157.
75. Vitali, L., et al. 2002. Roscovitine inhibits ongoing DNA synthesis in human cervical cancer. Cancer Lett. 180:7-12. (Pubitemid 34242959)
76. Wang, D., et al. 2001. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J. Virol. 75: 7266-7279. (Pubitemid 32737985)
77. Wang, L., et al. 2002. Inhibition of HTLV-1 transcription by cyclin dependent kinase inhibitors. Mol. Cell. Biochem. 237:137-153.
78. Wang, Y., J. E. Finan, J. M. Middeldorp, and S. D. Hayward. 1997. P32/TAP, a cellular protein that interacts with EBNA-1 of Epstein-Barr virus. Virology 236:18-29.
79. Welch, W. J., and J. R. Feramisco. 1984. Nuclear and nucleolar localization of the 72,000-dalton heat shock protein in heat-shocked mammalian cells. J. Biol. Chem. 259:4501-4513.
80. Wu, H., P. Kapoor, and L. Frappier. 2002. Separation of the DNA replication, segregation, and transcriptional activation functions of Epstein-Barr nuclear antigen 1. J. Virol. 76:2480-2490. (Pubitemid 34150716)
81. Yates, J., N. Warren, D. Reisman, and B. Sugden. 1984. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc. Natl. Acad. Sci. U. S. A. 81:3806-3810.
82. Yates, J. L., and S. M. Camiolo. 1988. Dissection of DNA replication and enhancer activation functions of Epstein-Barr virus nuclear antigen 1. Cancer Cells 6:197-205.
83. Yates, J. L., N. Warren, and B. Sugden. 1985. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313: 812-815. (Pubitemid 15130835)
84. Yin, Q., and E. K. Flemington. 2006. siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells. Virology 346:385-393.
85. Young, L., et al. 1989. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N. Engl. J. Med. 321:1080-1085.
86. Yu, J., et al. 2010. Protein arginine methyltransferase 1 regulates herpes simplex virus replication through ICP27 RGG-box methylation. Biochem. Biophys. Res. Commun. 391:322-328.
87. Zhu, J., et al. 2009. Protein array identification of substrates of the Epstein- Barr virus protein kinase BGLF4. J. Virol. 83:5219-5231.